Abstract
Novel methods of T-cell depletion either ex – or in-vivo has led to an increase use of haploidentical donor for allogeneic stem cell transplantation in patients with non-malignant diseases, who are lacking a HLA identical sibling or compatible unrelated donor. T-cell depletion by CD34+ cell selection resulted in relative high risk of graft failure with exception of SCIDs. Further refinement has been reported for selected depletion of α/β T-cells and CD19/B-lymphocytes. Risk of graft failure is relative high, but may be overcome by suicide gene-modified T-cells after haploidentical stem cell transplantion. T-cell repleted stem cell transplantation is an alternative method either with Anti-Thymocyte Globulin or post-transplant cyclophosphamide for haploidentical stem cell transplantation. Here the incidence of GvHD seems to be higher and longer follow-up is needed.
Keywords
- Haploidentical Stem Cell Transplantation
- Post-transplant Cyclophosphamide
- Graft-versus-host Disease (GvHD)
- Severe Combined Immunodeficiency (SCID)
- Haploidentical Donors
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017. doi: 10.1038/bmt.2017.34. [Epub ahead of print].
Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371(14):339–49.
Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339(17):1186–93.
Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006;38(4):291–7.
Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98(12):3456–64.
Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, et al. HLA-hapolidentical stem cell transplantation after removal of α/β+ T and B cells in children with nonmalignant disorders. Blood. 2014;124(5):822–6.
Clay J, Kulasekararaj AG, Potter V, Grimaldi F, McLorman D, Raj K, et al. Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2014;20(11):1711–6.
Esteves I, Bonfim C, Pasquini R, Funke V, Pereira NF, Rocha V, et al. Haploidentical BMT and post-transplant cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transplant. 2015;50(5):685–9.
Xu LP, Wang SQ, Wu DP, Wang JM, Gao SJ, Jiang M, et al. Haplo-identical transplantation for acquired severe aplastic anaemia in a multicenter prospective study. Br J Haematol. 2016;175(2):265–74.
Gao L, Li Y, Zhang Y, Chen X, Gao L, Zhang C, et al. Long-term outcome of HLA-haploidentical hematopoietic SCT without invitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy. Bone Marrow Transplant. 2014;49(4):519–24.
Xu LP, Jin S, Wang SQ, Xia LH, Bai H, Gao SJ, et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. J Hematol Oncol. 2017;10(1):25.
Sodanin P, Isgro A, Gaziev J, Polchi P, Paciaroni K, Marziali M, et al. Purified T-depleted CD34+ peripheral blood and bone marrow celltransplantation from haploidentical mother to child with thalassemia. Blood. 2010;115(6):1296–302.
Anurathapan U, Hongeng S, Pakakasama S, Sirachainan N, Songdej D, Chuansumrit A, et al. Hematopoietic stem cell transplantation for homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients from haploidentical donors. Bone Marrow Transplant. 2016;51(6):813–8.
Dallas MH, Triplett B, Shook DR, Hartford C, Srinivasan A, Laver J, et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2013;19(5):820–30.
Brodsky RA, Luznik L, Bolanos-Meade J, Leffell MS, Jones RJ, Fuchs EJ. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic disease. Bone Marrow Transplant. 2008;42(8):523–7.
Bolanos-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120(22):4285–91.
Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, Dupont B, et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood. 1983;61(2):341–8.
Railey MD, Lokhnygina Y, Buckley RH. Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone transplants without pretransplant chemotherapy or post-transplant GvHD prophylaxis. J Pediatr. 2009;155(6):834–40.
Antoine C, Muller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J, et al. Long-term survival and transplantation of haematopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet. 2003;361(9357):553–60.
Fernandes JF, Rocha V, Labopin M, Neven B, Moshous D, Gennery AR, et al. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? Blood. 2012;119(12):2949–55.
Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severee combined immunodeficiency, 2000–2009. N Engl J Med. 2014;371(5):434–46.
Merli P, Bartaina A, Li Pira G, Pende D, Falco M, Pagliana D, et al. Infusion of donor cells transduced with inducible Caspase 9 (BPX-501 cells) is a safe and effective strategy to accelerate immune recovery in patients with non-malignant disorders after T cell depleted haplo-HSCT. Bone Marrow Transplant. 2016;51:S4–5.
Jaiswal SR, Chakrabarti A, Chatterjee S, Ray K, Chakrabarti S. Haploidentical transplantation in children with unmanipulated peripheral blood stem cell graft: the need to look beyondpost-transplantation cyclophosphamide in younger children. Pediatr Transplant. 2016;20(5):675–82.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Kröger, N. (2017). Applications of Haploidentical SCT in Patients with Non-malignant Diseases. In: Demirer, T. (eds) Haploidentical Stem Cell Transplantation. Stem Cell Biology and Regenerative Medicine. Humana Press, Cham. https://doi.org/10.1007/978-3-319-65319-8_10
Download citation
DOI: https://doi.org/10.1007/978-3-319-65319-8_10
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-65318-1
Online ISBN: 978-3-319-65319-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)